Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Other hematologic neoplasm 2Plasma cell 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Melanoma 426Carcinoma, Non-Small-Cell Lung 92Neoplasm Metastasis 69Neoplasms 60Carcinoma, Renal Cell 54Lymphoma, T-Cell, Cutaneous 52Ovarian Neoplasms 46Squamous Cell Carcinoma of Head and Neck 42Breast Neoplasms 40Colorectal Neoplasms 38Stomach Neoplasms 37Skin Neoplasms 35Lymphoma 32Uveal Melanoma 31Mycosis Fungoides 31Carcinoma, Merkel Cell 31Triple Negative Breast Neoplasms 29Lung Neoplasms 29Sezary Syndrome 28Lymphoma, Non-Hodgkin 28Lymphoma, Follicular 27Hodgkin Disease 27Pancreatic Neoplasms 26Uterine Cervical Neoplasms 25Sarcoma 25Lymphoma, Large B-Cell, Diffuse 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, B-Cell, Marginal Zone 23Carcinoma, Hepatocellular 23Lymphoma, Mantle-Cell 22

Interventions

TPI-287 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Disease Progression × Dermatologic × Clear all
NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡